Dynavax Technologies Corporation (DVAX) and Apricus Biosciences Inc. (NASDAQ:APRI) Contrasting side by side

We will be contrasting the differences between Dynavax Technologies Corporation (NASDAQ:DVAX) and Apricus Biosciences Inc. (NASDAQ:APRI) as far as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dynavax Technologies Corporation 2.90M 221.29 146.35M -2.36 0.00
Apricus Biosciences Inc. N/A 0.00 N/A -0.53 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Dynavax Technologies Corporation and Apricus Biosciences Inc.

Profitability

Table 2 represents Dynavax Technologies Corporation (NASDAQ:DVAX) and Apricus Biosciences Inc. (NASDAQ:APRI)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dynavax Technologies Corporation -5,046.55% -98.6% -57.7%
Apricus Biosciences Inc. 0.00% -217.8% -154.2%

Risk & Volatility

Dynavax Technologies Corporation’s volatility measures that it’s 53.00% less volatile than Standard & Poor’s 500 due to its 0.47 beta. Apricus Biosciences Inc. has a 0.77 beta and it is 23.00% less volatile than Standard & Poor’s 500.

Analyst Recommendations

The Ratings and Recommendations for Dynavax Technologies Corporation and Apricus Biosciences Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Dynavax Technologies Corporation 0 0 1 3.00
Apricus Biosciences Inc. 0 0 0 0.00

$25 is Dynavax Technologies Corporation’s consensus price target while its potential upside is 144.14%.

Institutional and Insider Ownership

Institutional investors held 77.7% of Dynavax Technologies Corporation shares and 24.8% of Apricus Biosciences Inc. shares. About 0.7% of Dynavax Technologies Corporation’s share are held by insiders. Insiders Comparatively, held 1.6% of Apricus Biosciences Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dynavax Technologies Corporation -3.81% -9.94% -14.07% -31.2% -38.41% -41.87%
Apricus Biosciences Inc. -9.8% -21.3% 4.15% -35.42% -84.32% -85%

For the past year Dynavax Technologies Corporation was less bearish than Apricus Biosciences Inc.

Summary

Dynavax Technologies Corporation beats on 7 of the 10 factors Apricus Biosciences Inc.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodyÂ’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The companyÂ’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of RaynaudÂ’s Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.